Chitomur

Chitomur is a peptide bioregulator from Professor Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, derived from bladder/urothelial tissue, targeting the lower urinary tract.

Age-related changes in the lower urinary tract are among the most prevalent complaints of aging: reduced bladder capacity, impaired detrusor muscle contractility, increased post-void residual volume, nocturia, and urgency incontinence. In men, these changes are often compounded by benign prostatic hyperplasia; in women, by pelvic floor changes after menopause.

In the Khavinson bioregulator framework, Chitomur targets the urothelium (the specialized epithelium lining the bladder) and detrusor smooth muscle, proposing to support gene expression patterns that maintain normal bladder capacity, detrusor compliance, and barrier function.

Chitomur is used in the context of comprehensive urogenital anti-aging protocols in Eastern European clinical research settings. It is often combined with Prostamax (prostate bioregulator) in men and with systemic anti-aging protocols including Epithalon and Thymalin.

The evidence base for Chitomur follows the same pattern as other Khavinson bioregulators — primarily publications from the Russian-language gerontological literature with limited independent replication. The mechanistic plausibility rests on the Khavinson short peptide-DNA interaction model.